mardi 14 avril 2020

Onco Actu du 14 avril 2020


3.3 PRÉVENTION - VACCINS



Single Dose of HPV Vaccine Yields Long-Term Protection from Many Cancer-Causing Types [NCI]










4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...



FDA Releases Guidance Outlining Considerations for CDx Labeling for Oncology Drug Groups [Genome Web]











Companion Diagnostics: FDA Finalizes Guidance to Broaden Labeling for Precision Oncology [RAPS]











Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products [FDA]










4.2 DÉP., DIAG. & PRONO. - GÉNOME



Pediatric Low-Grade Glioma Molecular and Clinical Analysis Defines Subtypes That Predict Outcome [Genome Web]











Analysis of Advanced, Metastatic Tumors Indicates How Treatment Influences Mutational Profiles [Genome Web]











5. TRAITEMENTS



Who Benefits from Herceptin and Other Anti-HER2 Cancer Therapies? [The Scientist]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



Tailoring treatment for triple-negative breast cancer [Penn Today]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Tumors hijack the cell death pathway to live [UT Southwestern]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis [BeiGene]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Judge slaps enhanced damages on Gilead/Kite for ‘willful’ patent violation, boosting award to a blockbuster $1.2B — with the meter running [EndPoints]











5.2 PHARMA



AstraZeneca stops lung cancer trial early, after star drug Tagrisso induces 'overwhelming' efficacy [EndPoints]











AstraZeneca's top-selling cancer drug sees early unblinding in key trial [Reuters]











Tagrisso Phase III ADAURA trial will be unblinded early after overwhelming efficacy in the adjuvant treatment of patients with EGFR-mutated lung cancer [AstraZeneca]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



AstraZeneca, Merck finally grab a green light for rare-disease med Koselugo [Fierce Pharma]











AstraZeneca and Merck drug wins approval for rare cancer after failing elsewhere [Biopharma Dive]










KOSELUGO® (selumetinib) Approved by FDA for Pediatric Patients Two Years and Older With Neurofibromatosis Type 1 and Symptomatic, Inoperable Plexiform Neurofibromas [Merck]











6.12 ETHIQUE



Nonresearch Pharmaceutical Industry Payments to Oncology Physician Editors [The Oncologist]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



Challenges In Managing Clinical Trials In Oncology In The COVID-19 Era [ESMO]











American Cancer Society Invites Study Participants to Help COVID-19 Tracking [ACS]











New COVID-19 Cancer Registry Aims to Understand Impact on Patients During Pandemic, Inform Future Care [ASCO]










Coronavirus is forcing breast cancer patients to make tough decisions [Los Angeles Times]